{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T02:16:30Z","timestamp":1783304190417,"version":"3.54.6"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-026-06018-7","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:24:29Z","timestamp":1778574269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term survival with nivolumab in a patient with renal cell carcinoma: a case report and review of the literature"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-7418","authenticated-orcid":false,"given":"Patricia","family":"Rioja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaida","family":"Morante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Neciosup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Vidaurre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"12","key":"6018_CR1","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451\u20138.","journal-title":"J Immunol"},{"issue":"1","key":"6018_CR2","first-page":"9056173","volume":"2018","author":"H Choudhry","year":"2018","unstructured":"Choudhry H, Helmi N, Abdulaal WH, Zeyadi M, Zamzami MA, Wu W, et al. Prospects of IL-2 in Cancer Immunotherapy. Biomed Res Int. 2018;2018(1):9056173.","journal-title":"Biomed Res Int"},{"issue":"3","key":"6018_CR3","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","volume":"13","author":"G Fyfe","year":"1995","unstructured":"Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688\u201396.","journal-title":"J Clin Oncol"},{"issue":"9","key":"6018_CR4","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"6018_CR5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1517\/14712598.2013.770836","volume":"13","author":"O Hamid","year":"2013","unstructured":"Hamid O, Carvajal RD. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther. 2013;13(6):847\u201361.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"6018_CR6","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.euf.2021.11.006","volume":"8","author":"MO Grimm","year":"2022","unstructured":"Grimm MO, Gr\u00fcnwald V, M\u00fcller-Huesmann H, Ivanyi P, Schostak M, von der Heyde E, et al. Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study. Eur Urol Focus. 2022;8(5):1289\u201399.","journal-title":"Eur Urol Focus"},{"key":"6018_CR7","doi-asserted-by":"publisher","first-page":"113589","DOI":"10.1016\/j.ejca.2024.113589","volume":"201","author":"L Mourey","year":"2024","unstructured":"Mourey L, Rainho LT, Dalban C, Carril-Ajuria L, Negrier S, Chevreau C, et al. Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study. Eur J Cancer. 2024;201:113589.","journal-title":"Eur J Cancer"},{"issue":"9","key":"6018_CR8","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1001\/jamaoncol.2016.0775","volume":"2","author":"S George","year":"2016","unstructured":"George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, et al. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. JAMA Oncol. 2016;2(9):1179.","journal-title":"JAMA Oncol"},{"issue":"6B","key":"6018_CR9","doi-asserted-by":"publisher","first-page":"E67","DOI":"10.1111\/bju.13260","volume":"117","author":"J Teishima","year":"2016","unstructured":"Teishima J, Kobatake K, Kitano H, Nagamatsu H, Sadahide K, Hieda K, et al. The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma. BJU Int. 2016;117(6B):E67-74.","journal-title":"BJU Int"},{"issue":"18","key":"6018_CR10","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","volume":"33","author":"DF McDermott","year":"2015","unstructured":"McDermott DF, Choueiri TK, Puzanov I, Hodi S, Drake CG, Brahmer JR, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013\u201320.","journal-title":"J Clin Oncol"},{"issue":"13","key":"6018_CR11","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","volume":"33","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2014;33(13):1430\u20137.","journal-title":"J Clin Oncol"},{"issue":"18","key":"6018_CR12","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1002\/cncr.33033","volume":"126","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126(18):4156\u201367.","journal-title":"Cancer"},{"key":"6018_CR13","first-page":"201","volume":"1","author":"L Mourey","year":"2024","unstructured":"Mourey L, Rainho LT, Dalban C, Carril-Ajuria L, Negrier S, Chevreau C, et al. Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study. Eur J Cancer. 2024;1:201.","journal-title":"Eur J Cancer"},{"issue":"19","key":"6018_CR14","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England J Med. 2015;373(19):1803\u201313.","journal-title":"New England J Med"},{"issue":"12","key":"6018_CR15","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England J Med. 2019;380(12):1116\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1816714.","journal-title":"New England J Med"},{"issue":"12","key":"6018_CR16","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Plimack ER, Souli\u00e8res D, Waddell T, Stus V, Gafanov R, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563\u201373.","journal-title":"Lancet Oncol"},{"issue":"5","key":"6018_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102994","volume":"9","author":"T Powles","year":"2024","unstructured":"Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, et al. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial\u2606. ESMO Open. 2024;9(5): 102994. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102994.","journal-title":"ESMO Open"},{"issue":"10","key":"6018_CR18","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1136\/jitc-2021-003473","volume":"9","author":"A Tzeng","year":"2021","unstructured":"Tzeng A, Tzeng TH, Ornstein MC. Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis. J Immunother Cancer. 2021;9(10):3473.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"6018_CR19","doi-asserted-by":"publisher","first-page":"102181","DOI":"10.1016\/j.clgc.2024.102181","volume":"22","author":"MC Ornstein","year":"2024","unstructured":"Ornstein MC, George L, Wei W, Diaz-Montero CM, Rayman P, Martin A, et al. Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab. Clin Genitourin Cancer. 2024;22(6):102181.","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"6018_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.960751","volume":"12","author":"D Bimbatti","year":"2022","unstructured":"Bimbatti D, Dionese M, Lai E, Cavasin N, Basso U, Mattana A, et al. Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience. Front Oncol. 2022;12(12): 960751.","journal-title":"Front Oncol"},{"issue":"3","key":"6018_CR21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.eururo.2017.03.037","volume":"72","author":"B Escudier","year":"2017","unstructured":"Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with Nivolumab in CheckMate 025. Eur Urol. 2017;72(3):368\u201376.","journal-title":"Eur Urol"},{"issue":"2","key":"6018_CR22","doi-asserted-by":"publisher","first-page":"39.e19","DOI":"10.1016\/j.urolonc.2016.10.001","volume":"35","author":"N Tanaka","year":"2017","unstructured":"Tanaka N, Mizuno R, Yasumizu Y, Ito K, Shirotake S, Masunaga A, et al. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model. Urol Oncol. 2017;35(2):39.e19-39.e28.","journal-title":"Urol Oncol"},{"issue":"1","key":"6018_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/bju.12494","volume":"114","author":"B Beuselinck","year":"2014","unstructured":"Beuselinck B, Vano YA, Oudard S, Wolter P, De Smet R, Depoorter L, et al. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int. 2014;114(1):81\u20139.","journal-title":"BJU Int"},{"issue":"7","key":"6018_CR24","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1038\/bjc.2013.522","volume":"109","author":"M Santoni","year":"2013","unstructured":"Santoni M, De Giorgi U, Iacovelli R, Conti A, Burattini L, Rossi L, et al. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer. 2013;109(7):1755.","journal-title":"Br J Cancer"},{"issue":"4","key":"6018_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11523-019-00660-6","volume":"14","author":"H Ishihara","year":"2019","unstructured":"Ishihara H, Tachibana H, Takagi T, Kondo T, Fukuda H, Yoshida K, et al. Predictive impact of peripheral blood markers and C-reactive protein in Nivolumab therapy for metastatic renal cell carcinoma. Target Oncol. 2019;14(4):453\u201363.","journal-title":"Target Oncol"},{"issue":"1","key":"6018_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-024-02059-y","volume":"23","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Jin Y, Zhou J, Chen F, Chen M, Gao Z, et al. PD1\/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives. Mol Cancer. 2024;23(1):1\u201320. https:\/\/doi.org\/10.1186\/s12943-024-02059-y.","journal-title":"Mol Cancer"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06018-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06018-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06018-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T02:01:47Z","timestamp":1783303307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06018-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6018"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06018-7","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient provided written informed consent for the publication of this case report and accompanying images. This case report was approved by the local institutional review board of the Oncosalud- AUNA, Lima, Peru.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. All authors agreed to the submission and publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest that could appear to influence the results of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"371"}}